October 2, 2025
1 min read

Vaxcyte strikes up to $1B deal for fill-finish space at Thermo Fisher’s N.C. production facility

Vaxcyte is paying Thermo Fisher Scientific up to $1 billion to access vaccine fill-finish capacity at the CDMO’s production facility in Greenville, North Carolina. Vaxcyte positioned the deal as a “long-term U.S. commercial manufacturing commitment.”

Leave a Reply

Your email address will not be published.

Previous Story

Ansa snares $54.4M in series B financing to boost its DNA synthesis platform

Next Story

Cidara snares up to $339M from BARDA to bankroll its non-vaccine flu candidate

Previous Story

Ansa snares $54.4M in series B financing to boost its DNA synthesis platform

Next Story

Cidara snares up to $339M from BARDA to bankroll its non-vaccine flu candidate

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop